Slaptech Biomedical Technology Co., Ltd. announced the completion of Series A financing of over 50 million US dollars. This round of financing was led by Decheng Capital, followed by Huatai Kingsley Fund and China Merchants Venture Capital. The old shareholders Morningstar Venture Capital, Shunwei Capital, and Qianju Capital continued to add additional support. This round of funding will focus on advancing clinical development of core pipelines SP-101 and SP-201, and optimization of the i-NAS and SYNX dual-technology platforms.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.